- Home
- RDHL vs BIAF Comparison
RDHL vs BIAF Comparison
Compare RDHL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | BIAF |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Israel | United States |
| Employees | N/A | 57 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.6M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDHL | BIAF |
|---|---|---|
| Price | $1.00 | $1.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.9K | ★ 182.8K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $381.91 | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.23 |
| 52 Week High | $3.31 | $13.50 |
Technical Indicators
Market Signals| Indicator | RDHL | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 39.35 |
| Support Level | $0.92 | $1.23 |
| Resistance Level | $1.07 | $1.79 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 52.63 | 41.04 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.